SHAREHOLDER ALERT: Weiss Law Investigates Concert Pharmaceuticals, Inc.

NEW YORK, Jan. 19, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Concert Pharmaceuticals, Inc. ("Concert" or the "Company") (NASDAQ: CNCE), in connection with the proposed acquisition of the Company by Sun Pharmaceutical Industries Limited via tender offer. Under the terms of the merger agreement, the Company's shareholders will receive $8.00 in cash for each share of Concert common stock owned, plus one non-tradeable contingent value right ("CVR") per share. Each CVR will entitle its holder to deferred cash payments of $3.50 per CVR.